adjuvant

(redirected from Adjuvant therapy)
Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.
Related to Adjuvant therapy: Adjuvant chemotherapy

adjuvant

[′aj·ə·vənt]
(pharmacology)
A material that enhances the action of a drug or antigen.
References in periodicals archive ?
This study presents an innovative approach to constructing a summary measure of "guideline-concordance" when there are multiple possible treatment components (here, different types of adjuvant therapy following breast cancer surgery) and the recommended treatment package for a patient is conditional on her particular clinical circumstances.
Trastuzumab as adjuvant therapy for early breast cancer, the importance of accurate human epidermal growth factor receptor 2 testing.
The significance of anterior segment invasion as a putative risk factor for extraocular relapse is uncertain and adjuvant chemotherapy has been recommended by some authors, (13,14) whereas some authors recommend withholding the adjuvant therapy in such cases.
The study is promising because there is currently no adjuvant therapy for HCC patients following curative resection.
Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment -- surgery with or without radiation therapy -- with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.
Newer chemotherapy agents have been studied in an effort to add to the convenience and efficacy of adjuvant therapy in patients with stage III colon cancer.
Accordingly, the three parties have launched a clinical study of immune cell therapy for postoperative adjuvant therapy in pancreatic cancer.
In addition to surgery, adjuvant therapy is used to kill any cancer cells that may have spread.
These poor outcomes were attributed to the selection of high-risk or recurrent cases requiring aggressive adjuvant therapy.
Spin-off issues that are actively being pursued include a) modeling the impact of using alternative, more biologically based natural disease history formulations, especially continuous time tumor growth models (which include microscopic fatal metastases that are initially undetectable); b) analyses for different racial, ethnic, and insurance-status groups; c) a unique Bayesian approach to update its prior estimates of treatment efficacy to obtain posterior estimates of community effectiveness of adjuvant therapy and mammography that best reproduce national mortality trends; d) geographically based analyses; e) the role of risk factors in breast cancer trends; and f) the potential impact of optimal screening intervals.
To date, 51 postmenopausal women with stage I or II breast cancer who were scheduled for adjuvant therapy have been enrolled.
For a copy of the report, ask for the Adjuvant Therapy for Breast Cancer Consensus Statement from the Office of Medical Applications of Research, NIH, Building 31, Room 1B03, 31 Center Drive MSC 2082, Bethesda, MD 20892-2082.